MCID: BRR002
MIFTS: 36

Barrett's Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett's Adenocarcinoma

MalaCards integrated aliases for Barrett's Adenocarcinoma:

Name: Barrett's Adenocarcinoma 12 15 72
Barrett Adenocarcinoma 12 17
Adenocarcinoma Arising in Barrett's Mucosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7941
NCIt 50 C7027
UMLS 72 C1332460

Summaries for Barrett's Adenocarcinoma

MalaCards based summary : Barrett's Adenocarcinoma, also known as barrett adenocarcinoma, is related to adenocarcinoma and gastrointestinal system disease. An important gene associated with Barrett's Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gastric cancer and Glioma. Affiliated tissues include lymph node, colon and heart, and related phenotypes are cellular and behavior/neurological

Related Diseases for Barrett's Adenocarcinoma

Diseases related to Barrett's Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.4 TP53 PTGS2 ERBB2 CDKN2A
2 gastrointestinal system disease 30.0 TP53 PTGS2 ERBB2 CDKN2A
3 xeroderma pigmentosum, complementation group d 30.0 OGG1 GSTP1 ERCC2
4 squamous cell carcinoma 29.9 TP53 PTGS2 GSTP1 ERBB2 CDKN2A
5 barrett esophagus 29.6 TP53 PTGS2 GSTP1 FHIT ERBB2 CDKN2A
6 xeroderma pigmentosum, variant type 29.5 TP53 RAD51 OGG1 ERCC2
7 gastric adenocarcinoma 29.0 TP53 PTGS2 FHIT ERBB2 CDKN2A
8 esophageal cancer 28.4 TP53 RAD51 PTGS2 GSTP1 FHIT ERBB2
9 protoplasmic astrocytoma 10.6 TP53 PTGS2
10 recurrent respiratory papillomatosis 10.6 TP53 PTGS2
11 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
12 pleomorphic adenoma carcinoma 10.6 TP53 ERBB2
13 non-proliferative fibrocystic change of the breast 10.6 TP53 ERBB2
14 uterine corpus serous adenocarcinoma 10.6 TP53 ERBB2
15 breast squamous cell carcinoma 10.6 TP53 ERBB2
16 uterine body mixed cancer 10.6 TP53 ERBB2
17 microglandular adenosis 10.5 TP53 ERBB2
18 bladder squamous cell carcinoma 10.5 TP53 CDKN2A
19 glioma susceptibility 1 10.5 TP53 ERBB2
20 keratinizing squamous cell carcinoma 10.5 TP53 CDKN2A
21 spitz nevus 10.5 TP53 CDKN2A
22 breast papillomatosis 10.5 ERBB2 CDKN2A
23 bowenoid papulosis 10.5 PTGS2 CDKN2A
24 bladder carcinoma in situ 10.5 TP53 CDKN2A
25 fallopian tube endometrioid adenocarcinoma 10.5 ERBB2 CDKN2A
26 scrotal carcinoma 10.5 TP53 CDKN2A
27 uterine corpus cancer 10.5 TP53 ERBB2
28 vulva squamous cell carcinoma 10.5 TP53 CDKN2A
29 bartholin's gland disease 10.5 TP53 CDKN2A
30 nasal cavity adenocarcinoma 10.5 TP53 CDKN2A
31 thoracic benign neoplasm 10.5 TP53 ERBB2
32 vulvar disease 10.5 TP53 CDKN2A
33 thyroid lymphoma 10.5 TP53 CDKN2A
34 breast benign neoplasm 10.5 TP53 ERBB2
35 anal squamous cell carcinoma 10.5 TP53 CDKN2A
36 vulval paget's disease 10.5 ERBB2 CDKN2A
37 gastric adenosquamous carcinoma 10.5 TP53 CDKN2A
38 glycogen-rich clear cell breast carcinoma 10.5 TP53 CDKN2A
39 balanitis xerotica obliterans 10.5 PTGS2 CDKN2A
40 oral leukoplakia 10.4 TP53 CDKN2A
41 uterus carcinoma in situ 10.4 TP53 CDKN2A
42 vulva adenocarcinoma 10.4 ERBB2 CDKN2A
43 cervix uteri carcinoma in situ 10.4 TP53 CDKN2A
44 anogenital venereal wart 10.4 TP53 CDKN2A
45 gastroesophageal reflux 10.4
46 meningeal melanomatosis 10.4 TP53 CDKN2A
47 dedifferentiated liposarcoma 10.4 TP53 CDKN2A
48 esophagus adenocarcinoma 10.4 TP53 PTGS2 ERBB2
49 ductal carcinoma in situ 10.4 TP53 PTGS2 ERBB2
50 stomach disease 10.4 TP53 PTGS2 ERBB2

Graphical network of the top 20 diseases related to Barrett's Adenocarcinoma:



Diseases related to Barrett's Adenocarcinoma

Symptoms & Phenotypes for Barrett's Adenocarcinoma

MGI Mouse Phenotypes related to Barrett's Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 ADIPOR1 ADIPOR2 CDKN2A ERBB2 ERCC2 OGG1
2 behavior/neurological MP:0005386 10.01 ADIPOR1 ADIPOR2 CDKN2A ERBB2 ERCC2 OGG1
3 homeostasis/metabolism MP:0005376 9.97 ADIPOR1 ADIPOR2 CDKN2A ERBB2 ERCC2 FHIT
4 adipose tissue MP:0005375 9.83 ADIPOR1 ADIPOR2 ERCC2 PTGS2 TP53
5 integument MP:0010771 9.73 CDKN2A ERBB2 ERCC2 FHIT PTGS2 TP53
6 liver/biliary system MP:0005370 9.63 ADIPOR1 ADIPOR2 CDKN2A OGG1 PTGS2 TP53
7 neoplasm MP:0002006 9.5 CDKN2A ERBB2 ERCC2 FHIT OGG1 PTGS2
8 skeleton MP:0005390 9.17 ADIPOR1 ADIPOR2 CDKN2A ERBB2 ERCC2 PTGS2

Drugs & Therapeutics for Barrett's Adenocarcinoma

Search Clinical Trials , NIH Clinical Center for Barrett's Adenocarcinoma

Genetic Tests for Barrett's Adenocarcinoma

Anatomical Context for Barrett's Adenocarcinoma

MalaCards organs/tissues related to Barrett's Adenocarcinoma:

41
Lymph Node, Colon, Heart, Testes, Bone, Endothelial, Smooth Muscle

Publications for Barrett's Adenocarcinoma

Articles related to Barrett's Adenocarcinoma:

(show top 50) (show all 296)
# Title Authors PMID Year
1
Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. 38
30927083 2019
2
Strong Intra-Esophageal Reflux May Contribute to the Development of Barrett's Adenocarcinoma and Affect the Localization. 38
31412336 2019
3
Host factors influence Barrett's carcinogenesis: findings from a mouse gastroduodenal reflux model. 38
30790117 2019
4
A Primary Barrett's Adenocarcinoma with a Squamous Cell Carcinoma Component. 38
31118396 2019
5
Endoscopic Treatment of Early Barrett's Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer. 38
30176662 2019
6
Buried Barrett's Adenocarcinoma Clearly Demonstrated with Acetic Acid Chromoendoscopy. 38
30166635 2018
7
Reduced ╬▒GlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer. 38
29658052 2018
8
Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths. 38
29223109 2018
9
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. 38
29351773 2018
10
Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction. 38
29393168 2018
11
Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. 38
29342161 2018
12
Minimally invasive esophagectomy for Barrett's adenocarcinoma. 38
30505964 2018
13
Tumor location is a risk factor for lymph node metastasis in superficial Barrett's adenocarcinoma. 38
28924592 2017
14
Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study. 38
28571591 2017
15
Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. 38
28425657 2017
16
Sex steroid hormones in relation to Barrett's esophagus: an analysis of the FINBAR Study. 38
28241109 2017
17
Laser Imaging Facilitates Early Detection of Synchronous Adenocarcinomas in Patients with Barrett's Esophagus. 38
27157857 2017
18
[Gastrointestinal Diseases in the Era without Helicobacter pylori infection. Topics: VII. Barrett Adenocarcinoma]. 38
30179407 2017
19
[Treatment Strategy for Esophagogastric Junction Carcinoma;Highly Controversial Topic in the Upper Gastrointestinal Malignancy]. 38
28174399 2017
20
Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. 38
29399538 2017
21
[Pathogenetic aspects in precursor lesions of gastrointestinal tumors]. 38
27638535 2016
22
Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma. 38
26186253 2016
23
[Endoscopic therapy of esophageal diseases]. 38
27307161 2016
24
A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma. 38
27220657 2016
25
Case of Barrett's adenocarcinoma with marked endoscopic morphological changes in Barrett's esophagus over a long follow-up period of 15 years. 38
26946036 2016
26
Feasibility of optical coherence tomography for the evaluation of Barrett's mucosa buried underneath esophageal squamous epithelium. 38
26583560 2016
27
Role of nitric oxide in the pathogenesis of Barrett's-associated carcinogenesis. 38
26909236 2016
28
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. 38
27932981 2016
29
Endoscopic Treatment of Early Barrett's Neoplasia: Expanding Indications, New Challenges. 38
27573769 2016
30
Submucosal invasion and risk of lymph node invasion in early Barrett's cancer: potential impact of different classification systems on patient management. 38
26668743 2015
31
[A Case of Synchronous Multiple Esophageal Cancers Composed of Squamous Cell Carcinoma and Barrett's Adenocarcinoma]. 38
26805207 2015
32
[Barrett's esophagus: its diagnosis and management in Japan]. 38
26165069 2015
33
Useful strategies to prevent severe stricture after endoscopic submucosal dissection for superficial esophageal neoplasm. 38
26109798 2015
34
Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. 38
25294533 2015
35
A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence. 38
24612412 2015
36
Strategy for prevention of cancers of the esophagus. 38
25266020 2014
37
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. 38
25133047 2014
38
Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. 38
24565073 2014
39
Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade. 38
24853183 2014
40
Barrett's esophagus in the patients with familial adenomatous polyposis. 38
23771323 2014
41
Endoscopic diagnosis of early Barrett's neoplasia: perspectives for advanced endoscopic technology. 38
24754238 2014
42
The evil lies below the surface: Subsquamous tumor extension in Barrett's adenocarcinoma. 38
26134612 2014
43
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. 38
23604115 2014
44
Clinical Efficacy of Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction. 38
26134607 2014
45
Reduced expression of ╬▒GlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus. 38
24117499 2014
46
[Challenges and limits for endoscopic resection of oesophageal and oesophagogastric cancer]. 38
24585194 2014
47
Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. 38
24496431 2014
48
Role of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo study. 38
25415190 2014
49
Different histological status of gastritis in superficial adenocarcinoma of the esophagogastric junction. 38
24220802 2014
50
Adenocarcinoma in long-segment Barrett's esophagus 44 years after total gastrectomy. 38
24968432 2013

Variations for Barrett's Adenocarcinoma

Copy number variations for Barrett's Adenocarcinoma from CNVD:

7 (show top 50) (show all 60)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39411 10 114900000 119100000 Gain ABLIM1 Barrett''s adenocarcinoma
2 39412 10 114900000 119100000 Gain AFAP1L2 Barrett''s adenocarcinoma
3 42467 10 34500000 38800000 Gain CCNY Barrett''s adenocarcinoma
4 42468 10 34500000 38800000 Gain CUL2 Barrett''s adenocarcinoma
5 65755 12 21200000 26300000 Gain SSPN Barrett''s adenocarcinoma
6 66184 12 26300000 27700000 Gain ARNTL2 Barrett''s adenocarcinoma
7 66185 12 26300000 27700000 Gain TM7SF3 Barrett''s adenocarcinoma
8 73111 12 91200000 94800000 Gain KRT19P2 Barrett''s adenocarcinoma
9 74577 13 109100000 114142980 Gain Barrett''s adenocarcinoma
10 75797 13 24400000 26700000 Gain Barrett''s adenocarcinoma
11 79796 13 77800000 86500000 Gain SOX1 Barrett''s adenocarcinoma
12 81034 14 100400000 102200000 Gain SLC25A29 Barrett''s adenocarcinoma
13 88798 14 95400000 100400000 Gain TCL1A Barrett''s adenocarcinoma
14 88799 14 95400000 100400000 Gain TCL1B Barrett''s adenocarcinoma
15 107009 17 11200000 15900000 Loss RICH2 Barrett''s adenocarcinoma
16 114436 17 47600000 54900000 Gain CUEDC1 Barrett''s adenocarcinoma
17 115246 17 55600000 58400000 Gain LRRC37A3 Barrett''s adenocarcinoma
18 116543 17 6800000 11200000 Loss MYH13 Barrett''s adenocarcinoma
19 116544 17 6800000 11200000 Loss TP53 Barrett''s adenocarcinoma
20 122243 18 54400000 57100000 Loss Barrett''s adenocarcinoma
21 125938 19 16100000 19800000 Gain AP1M1 Barrett''s adenocarcinoma
22 127254 19 30200000 37100000 Gain ZNF536 Barrett''s adenocarcinoma
23 134771 2 106700000 108600000 Gain GCC2 Barrett''s adenocarcinoma
24 141056 2 205600000 209100000 Gain Barrett''s adenocarcinoma
25 144816 2 29800000 31900000 Gain ALK Barrett''s adenocarcinoma
26 151523 20 22300000 25700000 Gain SSTR4 Barrett''s adenocarcinoma
27 151524 20 22300000 25700000 Loss CST4 Barrett''s adenocarcinoma
28 152533 20 31500000 33900000 Gain CEP250 Barrett''s adenocarcinoma
29 154854 20 49200000 54400000 Gain CBLN4 Barrett''s adenocarcinoma
30 170891 3 161200000 169200000 Gain BCHE Barrett''s adenocarcinoma
31 172565 3 184200000 186000000 Gain MAGEF1 Barrett''s adenocarcinoma
32 172566 3 184200000 186000000 Gain MUC13 Barrett''s adenocarcinoma
33 172567 3 184200000 186000000 Gain VPS8 Barrett''s adenocarcinoma
34 177566 3 58500000 63700000 Loss Barrett''s adenocarcinoma
35 196847 5 172200000 176500000 Gain MSX2 Barrett''s adenocarcinoma
36 203652 6 1 2300000 Gain Barrett''s adenocarcinoma
37 204555 6 11200000 13500000 Gain PHACTR1 Barrett''s adenocarcinoma
38 205460 6 127300000 130400000 Gain C6orf190 Barrett''s adenocarcinoma
39 205461 6 127300000 130400000 Gain PTPRK Barrett''s adenocarcinoma
40 212308 6 36800000 40600000 Gain DNAH8 Barrett''s adenocarcinoma
41 219021 7 120900000 123600000 Loss SLC13A1 Barrett''s adenocarcinoma
42 219022 7 120900000 123600000 Loss TAS2R16 Barrett''s adenocarcinoma
43 225150 7 43300000 46600000 Gain RAMP3 Barrett''s adenocarcinoma
44 225833 7 50900000 53900000 Gain Barrett''s adenocarcinoma
45 227260 7 66100000 71800000 Gain CALN1 Barrett''s adenocarcinoma
46 227261 7 66100000 71800000 Gain WBSCR17 Barrett''s adenocarcinoma
47 227796 7 7200000 13300000 Gain ICA1 Barrett''s adenocarcinoma
48 231014 8 101600000 106100000 Gain ANKRD46 Barrett''s adenocarcinoma
49 231021 8 101600000 106100000 Gain RNF19 Barrett''s adenocarcinoma
50 232059 8 110600000 112200000 Gain PKHD1L1 Barrett''s adenocarcinoma

Expression for Barrett's Adenocarcinoma

Search GEO for disease gene expression data for Barrett's Adenocarcinoma.

Pathways for Barrett's Adenocarcinoma

Pathways related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 TP53 GSTP1 ERBB2 CDKN2A
2
Show member pathways
12.44 TP53 FHIT ERBB2 CDKN2A
3
Show member pathways
12.4 TP53 RAD51 GSTP1 ERBB2 CDKN2A
4
Show member pathways
12.39 TP53 RAD51 OGG1 ERCC2
5 12.16 TP53 PTGS2 ERBB2 CDKN2A
6 12.16 TP53 RAD51 PTGS2 GSTP1 ERBB2 CDKN2A
7 12.02 TP53 RAD51 GSTP1 ERCC2 CDKN2A
8
Show member pathways
11.85 TP53 ADIPOR2 ADIPOR1
9 11.82 TP53 ERCC2 CDKN2A
10 11.67 TP53 ERBB2 CDKN2A
11 11.54 TP53 PTGS2 FHIT
12 11.48 TP53 ERCC2 CDKN2A
13 11.36 TP53 ERBB2 CDKN2A
14 11.1 TP53 CDKN2A
15 11.05 GSTP1 ERCC2
16 11.04 TP53 RAD51
17
Show member pathways
10.88 TP53 CDKN2A
18 10.87 TP53 CDKN2A
19 10.79 TP53 GSTP1 ERBB2 CDKN2A
20 10.63 PTGS2 GSTP1

GO Terms for Barrett's Adenocarcinoma

Cellular components related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.1 TP53 RAD51 OGG1 GSTP1 FHIT CDKN2A

Biological processes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.81 TP53 RAD51 OGG1 ERCC2
2 aging GO:0007568 9.71 PTGS2 OGG1 ERCC2
3 fatty acid metabolic process GO:0006631 9.67 PTGS2 ADIPOR2 ADIPOR1
4 response to oxidative stress GO:0006979 9.65 PTGS2 OGG1 ERCC2
5 negative regulation of apoptotic process GO:0043066 9.62 TP53 PTGS2 OGG1 GSTP1
6 response to estradiol GO:0032355 9.58 PTGS2 OGG1 GSTP1
7 negative regulation of fibroblast proliferation GO:0048147 9.56 TP53 GSTP1
8 regulation of ERK1 and ERK2 cascade GO:0070372 9.55 GSTP1 ERBB2
9 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.52 TP53 FHIT
10 fatty acid oxidation GO:0019395 9.46 ADIPOR2 ADIPOR1
11 replicative senescence GO:0090399 9.43 TP53 CDKN2A
12 regulation of fatty acid biosynthetic process GO:0042304 9.37 ADIPOR2 ADIPOR1
13 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 ERBB2 CDKN2A
14 adiponectin-activated signaling pathway GO:0033211 9.16 ADIPOR2 ADIPOR1
15 nucleotide-excision repair GO:0006289 9.13 TP53 OGG1 ERCC2
16 negative regulation of cell growth GO:0030308 8.92 TP53 CDKN2A ADIPOR2 ADIPOR1

Molecular functions related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.67 TP53 ERBB2 ADIPOR2 ADIPOR1
2 identical protein binding GO:0042802 9.63 TP53 RAD51 FHIT ERBB2 ADIPOR2 ADIPOR1
3 protein kinase binding GO:0019901 9.62 TP53 GSTP1 CDKN2A ADIPOR1
4 protein C-terminus binding GO:0008022 9.58 RAD51 ERCC2 ERBB2
5 nucleotide binding GO:0000166 9.56 RAD51 FHIT ERCC2 ERBB2
6 adiponectin binding GO:0055100 8.96 ADIPOR2 ADIPOR1
7 adipokinetic hormone receptor activity GO:0097003 8.62 ADIPOR2 ADIPOR1

Sources for Barrett's Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....